Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer presents considerable treatment challenges owing to its aggressive nature. Global guidelines have endorsed a full year of HER2-targeted therapy for early-stage breast cancer. However, previous cost-effectiveness analyses of dual...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical drug investigation 2024-12, Vol.44 (12), p.927-938
Hauptverfasser:	Nusawat, Chanon, Sato, So, Watanabe, Hideaki, Konishi, Takaaki, Yamana, Hayato, Yasunaga, Hideo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - economics Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - economics Breast Neoplasms - pathology Cancer therapies Chemotherapy Chemotherapy, Adjuvant - economics Chemotherapy, Adjuvant - methods Clinical trials Cost analysis Cost-Benefit Analysis Cost-Effectiveness Analysis Epidermal growth factor Female Health care expenditures Humans Japan Markov Chains Metastasis Middle Aged Monte Carlo Method Original Patients Quality-Adjusted Life Years Receptor, ErbB-2 - metabolism Remission (Medicine) Trastuzumab - administration & dosage Trastuzumab - economics Trastuzumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!